

REMARKS

This is intended to be a complete response to the Official Action mailed February 2, 2007, in which claims 17-18 and 24-26 were rejected in a final action. Applicants respectfully submit amendments to the claims which Applicants believe places the claims in a condition for allowance. Claims 1-16 and 19-23 have previously been cancelled without prejudice. Claims 17-18 and 24 have been amended herein. Claims 17, 18, and 24-26 remain in this application.

REJECTION UNDER 35 U.S.C. §112 ¶1

Claims 17-18 and 24-26 stand rejected under 35 U.S.C. 112, first paragraph, as

"failing to comply with the written description requirement and while being enabling for an expression system comprising an isolated recombinant host cell comprising a polynucleotide encoding the polypeptide of SEQ ID NO.:1 and a polynucleotide encoding the human core 1 β 3-galactosyltransferase as described in pages 50-54 of the specification, does not reasonably provide enablement for an expression system comprising (1) a nucleic acid which encodes any core 1 β 3-galactosyltransferase activated by (i) the chaperone of SEQ ID NO.:1, or (ii) structural homologs of the chaperone of SEQ ID NO.:1, and (2) a nucleic acid which hybridizes under the conditions recited to the polynucleotide of SEQ ID NO.:2 and encodes a protein which would activate any core 1 β 3-galactosyltransferase."

Applicants respectfully traverse the rejection on the basis that the invention is adequately described and enabled in that it requires only routine experimentation for a person of ordinary skill in the art to determine if any

given protein has core 1 β 3-galactosyltransferase specific molecular chaperone activity.

However, in the interest of advancing the prosecution, Applicants have amended the claims without prejudice to indicate that (1) the core 1 β 3-galactosyltransferase which is encoded by the first expressible polynucleotide is a human core 1 β 3-galactosyltransferase, and (2) the second expressible recombinant polynucleotide which encodes the human core 1 β 3-galactosyltransferase specific molecular chaperone is either SEQ ID NO.:2, or a polynucleotide sequence which differs in nucleotide sequence from SEQ ID NO.:2 due to the degeneracy of the genetic code and which encodes human core 1 β 3 galactosyltransferase specific molecular chaperone protein, or is a sequence like the other second expressible recombinant polynucleotides except it encodes a core 1 β 3-galactosyltransferase specific molecular chaperone which is soluble.


Further, it is noted that no new matter has been added to the claims. Further, the Examiner has acknowledged that the specification enables human core 1 β 3-galactosyltransferase (page 4, lines 204). Further, the claims have not been broadened, and thus no new search of the art is necessary.

In view of the amendments made herein, Applicants respectfully request reconsideration and withdrawal of the rejections under 35 U.S.C. §112 ¶1.

CONCLUSION

In view of the above amendments submitted herewith under 37 C.F.R. §1.116, Applicants respectfully submit the claims are now in a condition for allowance and thus request issuance of a Notice of Allowance therefor.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Christopher W. Corbett", is written over a horizontal line.

Christopher W. Corbett

Reg. No. 36,109

DUNLAP CODDING & ROGERS, P.C.

P.O. Box 16370

Oklahoma City, Oklahoma 73113

Telephone: 405/607-8600

Facsimile: 405/607-8686

Agent for Applicants